Michael Skynner Sells 972 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) Stock

Bicycle Therapeutics plc (NASDAQ:BCYCGet Free Report) CTO Michael Skynner sold 972 shares of the firm’s stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total value of $21,636.72. Following the transaction, the chief technology officer now owns 92,945 shares in the company, valued at $2,068,955.70. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Bicycle Therapeutics Price Performance

NASDAQ BCYC opened at $23.60 on Monday. The firm has a market capitalization of $1.01 billion, a PE ratio of -5.30 and a beta of 0.89. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.77 and a quick ratio of 14.77. Bicycle Therapeutics plc has a 12 month low of $12.54 and a 12 month high of $28.20. The company’s 50 day simple moving average is $23.36 and its 200 day simple moving average is $22.90.

Bicycle Therapeutics (NASDAQ:BCYCGet Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.33. Bicycle Therapeutics had a negative return on equity of 32.80% and a negative net margin of 417.88%. The company had revenue of $9.36 million for the quarter, compared to the consensus estimate of $6.13 million. The business’s quarterly revenue was down 17.9% compared to the same quarter last year. As a group, equities research analysts forecast that Bicycle Therapeutics plc will post -3.17 EPS for the current fiscal year.

Hedge Funds Weigh In On Bicycle Therapeutics

Hedge funds have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD boosted its position in shares of Bicycle Therapeutics by 45.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 401,646 shares of the company’s stock valued at $10,001,000 after purchasing an additional 124,809 shares during the period. Parkman Healthcare Partners LLC boosted its holdings in shares of Bicycle Therapeutics by 155.0% in the fourth quarter. Parkman Healthcare Partners LLC now owns 312,889 shares of the company’s stock worth $5,657,000 after buying an additional 190,168 shares during the period. Westfield Capital Management Co. LP increased its position in shares of Bicycle Therapeutics by 13.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,038,917 shares of the company’s stock worth $25,869,000 after acquiring an additional 121,613 shares in the last quarter. TD Asset Management Inc raised its holdings in shares of Bicycle Therapeutics by 76.7% during the second quarter. TD Asset Management Inc now owns 97,186 shares of the company’s stock valued at $1,967,000 after acquiring an additional 42,200 shares during the period. Finally, Perceptive Advisors LLC purchased a new stake in shares of Bicycle Therapeutics in the 2nd quarter valued at approximately $11,577,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

Analysts Set New Price Targets

BCYC has been the subject of several research reports. Oppenheimer reaffirmed an “outperform” rating and issued a $48.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicycle Therapeutics in a research report on Monday, September 9th. Needham & Company LLC restated a “buy” rating and set a $38.00 price objective on shares of Bicycle Therapeutics in a research report on Monday, September 16th. JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 target price on shares of Bicycle Therapeutics in a research report on Monday, September 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Bicycle Therapeutics in a report on Monday, September 16th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Bicycle Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $44.56.

Get Our Latest Stock Analysis on BCYC

Bicycle Therapeutics Company Profile

(Get Free Report)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

Read More

Insider Buying and Selling by Quarter for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.